MEDVi review (2026)
MEDVi dispenses via 503A (unnamed). Compounded tirzepatide is from $179/mo (about $299 at maintenance). Semaglutide is from $179/mo (about $249 at maintenance). On our six-pillar rubric it passes some but not all criteria (missing: flat pricing).
Pricing
| Molecule | Advertised | True/mo | 12-mo | Membership | Labs |
|---|---|---|---|---|---|
| Tirzepatide | $179 | $299↑ | $3,588 | — | Incl |
| Semaglutide | $179 | $249↑ | $2,988 | — | Incl |
Dose-increase pricing: Rises with dose. Shipping: Free.
Pharmacy & clinical model
Pharmacy disclosure: 503A (unnamed). Medical review: named prescriber / clinician-supervised. Compliance: LegitScript or equivalent disclosed. Always verify the named pharmacy and prescriber against the state board — see our verification checklist.
State availability
MEDVi operates via 503A · inj + tablets. Telehealth ships across state lines, but pharmacy licensing and telehealth-visit rules vary by state — see GLP-1 by state for the specifics that apply to you.
Pros & cons
Refund & cancellation
Confirm the cancellation policy and whether auto-renew is on by default before enrolling. Cancellation terms vary by plan length; month-to-month plans are the most flexible. (Specific refund terms should be verified on MEDVi's site before publishing.)
Who MEDVi is best for — and who should look elsewhere
Best for: patients who want this provider’s specific program features. Look elsewhere if: you want flat pricing that won’t climb as you titrate up.
MEDVi vs NexLife
| Criterion | MEDVi | NexLife ★ |
|---|---|---|
| Tirzepatide true/mo | $299 | $186 |
| Semaglutide true/mo | $249 | $145 |
| Pricing model | Rises with dose | Flat |
| Pharmacy | 503A (unnamed) | 503A + 503B (named) |
| Passes full rubric | Partial | Yes |
Full NexLife vs MEDVi comparison →
How we evaluated MEDVi
Scored on our six-pillar rubric: true-price transparency, pharmacy traceability, prescriber model, regulatory posture, what's included, and plan terms. Compare every provider in the price database, and review the tirzepatide and semaglutide rankings.
Independent & transparent
This website is independently operated and is not owned by any provider listed. Some outbound links may be affiliate or sponsored links. Rankings are based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →